Syndax Pharmaceuticals Inc expected to post a loss of $1.02 a share - Earnings Preview

Syndax Pharmaceuticals

01/08/2025 22:07

Syndax Pharmaceuticals Inc SNDX.OQ SNDX.O is expected to  show a rise in quarterly revenue when it reports  results on August 4 for the period ending June 30 2025

The New York City-based  company is expected to report a 666.4% increase in revenue to $26.825 million from $3.5 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Syndax Pharmaceuticals Inc is for a loss of $1.02 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $33.50, about 70.4% above its last closing price of $9.92

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.20
-1.33
-0.98
Beat
26.4
Dec. 31 2025
-0.42
-0.23
-1.10
Missed
-380
Sep. 30 2024
-1.14
-1.11
-0.98
Beat
11.9​
Jun. 30 2024
-0.91
-0.91
-0.80
Beat
12.5
​​Mar. 31 2024
-0.96
-0.98
-0.85
Beat
13.1
Dec. 31 2023
-0.97
-0.99
-1.00
Missed
-0.6​
Sep. 30 2023
-0.80
-0.80
-0.73
Beat
8.2
Jun. 30 2023
-0.73
-0.73
-0.64
Beat
12.6

This summary was machine generated August 1 at 21:07 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)